Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and Type 2 diabetes

Clinica Chimica Acta

Volumn 413, Issue 9-10, 2012, Pages 927-932

  McDonald, Tim J ^a,b   McEneny, Jane ^c   Pearson, Ewan R ^a,d   Thanabalasingham, Gaya ^e,f   Szopa, Magdalena ^g,h   Shields, Beverley M ^a   Ellard, Sian ^a   Owen, Katharine R ^e,f   Malecki, Maciej T ^g,h   Hattersley, Andrew T ^a   Young, Ian S ^c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Diabetes; HNF1A MODY; Lipoproteins; Type 2 diabetes, HDL

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMEODOMAIN PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TRANSCRIPTION FACTOR HNF1A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LIPID ANALYSIS; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; MALE; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84858622767     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.02.005     Document Type: Article

References (33)

1. Blumenfeld M., Maury M., Chouard T., Yaniv M., Condamine H. Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development 1991, 113:589-599.
2. Shields B.M., Hicks S., Shepherd M.H., Colclough K., Hattersley A.T., Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing?. Diabetologia 2010, 53:2504-2508.
3. Tattersall R.B. Mild familial diabetes with dominant inheritance. Q J Med 1974, 43:339-357.
4. Tattersall R.B., Fajans S.S. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975, 24:44-53.
5. Pearson E.R., Flechtner I., Njolstad P.R., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006, 355:467-477.
6. Pearson E.R., Liddell W.G., Shepherd M., Corrall R.J., Hattersley A.T. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000, 17:543-545.
7. Dabelea D., Mayer-Davis E.J., Imperatore G. The value of national diabetes registries: SEARCH for Diabetes in Youth Study. Curr Diab Rep 2010, 10:362-369.
8. Owen K.R., Shepherd M., Stride A., Ellard S., Hattersley A.T. Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics. Diabet Med 2002, 19:758-761.
9. Stride A., Ellard S., Clark P., et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care 2005, 28:1751-1756.
10. Tripathy D., Carlsson A.L., Lehto M., Isomaa B., Tuomi T., Groop L. Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 2000, 43:1476-1483.
11. Rizzo M., Berneis K., Koulouris S., et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. Int J Clin Pract 2010, 64:1632-1642.
12. Pontoglio M., Barra J., Hadchouel M., et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996, 84:575-585.
13. Lee Y.H., Sauer B., Gonzalez F.J. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse. Mol Cell Biol 1998, 18:3059-3068.
14. Shih D.Q., Bussen M., Sehayek E., et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001, 27:375-382.
15. Pearson E.R., Badman M.K., Lockwood C.R., et al. Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations. Diabetes Care 2004, 27:1102-1107.
16. Steele A.M., Shields B.M., Shepherd M., Ellard S., Hattersley A.T., Pearson E.R. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010, 27:157-161.
17. Isomaa B., Henricsson M., Lehto M., et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998, 41:467-473.
18. Richter S., Shih D.Q., Pearson E.R., et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003, 52:2989-2995.
19. Skupien J., Kepka G., Gorczynska-Kosiorz S., et al. Evaluation of apolipoprotein M serum concentration as a biomarker of HNF-1alpha MODY. Rev Diabet Stud 2007, 4:231-235.
20. Karlsson E., Shaat N., Groop L. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?. Diabet Med 2008, 25:788-791.
21. McEneny J., Loughrey C.M., McNamee P.T., Trimble E.R., Young I.S. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 1997, 129:215-220.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Maron D.J. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000, 86:11L-14L.
24. Laing S.P., Swerdlow A.J., Slater S.D., et al. The British Diabetic Association Cohort Study, I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999, 16:459-465.
25. Hoang A., Murphy A.J., Coughlan M.T., et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007, 50:1770-1779.
26. Nobecourt E., Tabet F., Lambert G., et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010, 30:766-772.
27. Borggreve S.E., De Vries R., Dullaart R.P. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051-1069.
28. de Vries R., Borggreve S.E., Dullaart R.P. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003, 49:601-613.
29. Chapman M.J. Are the effects of statins on HDL-cholesterol clinically relevant?. Eur Heart J Suppl 2004, 6:C58-C63.
30. Shepherd M., Pearson E.R., Houghton J., Salt G., Ellard S., Hattersley A.T. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003, 26:3191-3192.
31. Shepherd M., Shields B., Ellard S., Rubio-Cabezas O., Hattersley A.T. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009, 26:437-441.
32. Owen K.R., Thanabalasingham G., James T.J., et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010, 33:1919-1924.
33. McDonald T.J., Shields B.M., Lawry J., et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011, 34:1860-1862.